Resources | boehringerone.com

VIDEOS

IPF does not wait - The Importance of Early Diagnosis

02:40

IPF does not wait - The Importance of Early Diagnosis

Evaluation FVC Data from Impulsis on Trial

02:12

Evaluation FVC Data from Impulsis on Trial

Ofev Mortality Data

02:22

Ofev Mortality Data

How does Nintedanib benefit patients in preserving lung function

03:02

How does Nintedanib benefit patients in preserving lung function

Effect On Honeycombing Efficacy

02:44

Effect On Honeycombing Efficacy

Efficacy with Concomitant Emphysema

03:16

Efficacy with Concomitant Emphysema

Expert Opinion

02:56

Expert Opinion

Acute Exacerbation

02:06

Acute Exacerbation

Survival Analysis

05:57

Survival Analysis

Mechanism of Action

03:19

Mechanism of Actions

Patient Subgroup Analysis

09:32

Patient Subgroup Analysis

Why was data of impulsis and tomorrow pooled?

02:03

Why was data of impulsis and tomorrow pooled?

Early Use of Antifibrotic

00:57

Early Use of Antifibrotic

INPULSIS-ON Prof. Richeldi & Prof. Maher video & transcript: New guideline Impact on the Diagnosis of IPF

01:06

INPULSIS-ON Prof. Richeldi & Prof. Maher video & transcript: New guideline Impact on the Diagnosis of IPF

Vincent Cottin discuss symptoms and signs of IPF

01:50

Vincent Cottin discuss symptoms and signs of IPF

Vincent Cottin discuss the impact of diagnosis on patients

01:06

Vincent Cottin discuss the impact of diagnosis on patients

Prof. Richeldi & Prof. Maher Video Transcript: Why watch & wait?

01:50

Prof. Richeldi & Prof. Maher Video Transcript: Why watch & wait?

OFEV - INPULSIS ON (Dr Maher- Dr Richaldi)

03:29

OFEV - INPULSIS ON (Dr Maher- Dr Richaldi)

Life Happens - Car Crash

00:52

Life Happens - Car Crash

Customer Journey

05:14

Customer Journey

RECIRCUIT - Video Infographic

02:04

RECIRCUIT - Video Infographic

Patient Elderly with Moderate Renal Impairment

03:10

Patient Elderly with Moderate Renal Impairment

Aortic Dissection Case

04:12

Aortic Dissection Case

Praxbind availabality

01:16

Praxbind availabality

Shower Fall

01:17

Shower Fall

Patient Infographic

02:58

Patient Infographic

Praxbind MOA

01:01

Praxbind MOA

What is the leading cause of death in patients with type 2 diabetes?

01:32

What is the leading cause of death in patients with type 2 diabetes?

What are your thoughts on the 35% relative risk reduction?

01:42

What are your thoughts on the 35% relative risk reduction?

Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it?

01:52

Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it?

What were the key findings from EMPA-REG OUTCOME?

02:29

What were the key findings from EMPA-REG OUTCOME?

Should we move beyond glucose lowering as the main treatment goal?

02:46

Should we move beyond glucose lowering as the main treatment goal?

What does lowering the risk of CV death? - John Wilding

01:56

What does lowering the risk of CV death? - John Wilding

Are patients with type 2 diabetes at elevated CV risk?

02:23

Are patients with type 2 diabetes at elevated CV risk?

Early reduction in CV death with Jardiance

01:01

Early reduction in CV death with Jardiance

Reduce the risk of mortality with Jardiance

01:01

Reduce the risk of mortality with Jardiance

Reduce the risk of hospitalization for heart failure with Jardiance

01:01

Reduce the risk of hospitalization for heart failure with Jardiance

Patients could benefit from Jardiance across baseline HbA1c

01:00

Patients could benefit from Jardiance across baseline HbA1c

Going beyond standard care of with Jardiance

01:03

Going beyond standard care of with Jardiance

Reduce the risk of CV death with Jardiance-38 Percent

01:01

Reduce the risk of CV death with Jardiance - 38%

Is Jardiance a medication for both endocrinologists and cardiologists?

02:23

Is Jardiance a medication for both endocrinologists and cardiologists?

What are your views on the 38% relative risk reduction in CV death with Jardiance?

02:22

What are your views on the 38% relative risk reduction in CV death with Jardiance?

What does lowering the risk of CV death? - Lars Ryden

01:51

What does lowering the risk of CV death? - Lars Ryden

What are your thoughts on the 35% relative risk reduction?

01:42

What are your thoughts on the 35% relative risk reduction?

Reduce the risk of CV death with Jardiance - 1/3

01:01

Reduce the risk of CV death with Jardiance - 1/3

Long term benefit of Jardiance on life expectancy

01:00

Long term benefit of Jardiance on life expectancy

Clinical studies

Combined evidence from the TOMORROW and INPULSIS® trials

Combined evidence from the TOMORROW and INPULSIS® trials

Instage Trial

Instage Trial

Acute Exacerbation and Decline in FVC

Acute Exacerbation and Decline in FVC

Is honeycombing in an HRCT, the sole detector of IPF?

Is honeycombing in an HRCT, the sole detector of IPF?

IPF Diagnosis According to ATS/ERS/JRS/ALAT Clinical Practice Guideline 2018

IPF Diagnosis According to ATS/ERS/JRS/ALAT Clinical Practice Guideline 2018

How does dosing and administration of Nintedanib help compliance of IPF patients

How does dosing and administration of Nintedanib help compliance of IPF patients?

Adverse Event Management

Adverse Event Management

Long-term Safety and Tolerability of Nintedanib in Patients with IPF

Long-term Safety and Tolerability of Nintedanib in Patients with IPF

Safety and Tolerability of Nintedanib

Safety and Tolerability of Nintedanib in Patients

Cardiovascular Safety of Nintedanib in Subgroups by Cardiovascular risk at Baseline in the Tomorrow and Impulsis Trials

Cardiovascular Safety of Nintedanib in Subgroups by Cardiovascular risk at Baseline in the Tomorrow and Impulsis Trials

Cardiovascular Safety of Ofev

Cardiovascular Safety of Ofev

Practical Guidance

Practical Guidance

OD vs BID

OD vs BID

RE-DUAL VS AUGUSTUS Infographic

RE-DUAL VS AUGUSTUS Infographic

RE-DUAL Subanalysis

RE-DUAL Subanalysis

RE-DUAL vs PIONEER - Efficacy Comparison

RE-DUAL vs PIONEER - Efficacy Comparison

RE-DUAL vs PIONEER - Dose Comparison

RE-DUAL vs PIONEER - Dose Comparison

RE-DUAL vs PIONEER - Complete Comparison

RE-DUAL vs PIONEER - Complete Comparison

RE-DUAL PDF

RE-DUAL PDF

Efficacy

Efficacy

Safety

Safety

Simplicity

Simplicity

Larsen RWD

Larsen RWD

Graham RWD

Graham RWD

LIN RWD

LIN RWD

Nielson RWD

Nielson RWD

RIVA Meta Analysis

RIVA Meta Analysis

Patients with Decline in Renal Function

Patients with Decline in Renal Function

Patients with Moderate Renal Impairment

Patients with Moderate Renal Impairment

Patients Below 75

Patients Below 75

RECIRCUIT - Trial

RECIRCUIT - Trial

RECIRCUIT - Summary Infographic

RECIRCUIT - Summary Infographic

MOA - NOAC Reversal Guidelines

MOA - NOAC Reversal Guidelines

MOA - Thrombolysis Patients

MOA - Thrombolysis Patients

EMPA-REG Outcome Study Design

EMPA-REG Outcome Study Design

EMPRISE reinforce the reduction in HHF

EMPRISE reinforce the reduction in HHF

EMPRISE reinforce the reduction in HHF

Jaridance Efficacy

EMPRISE reinforce the reduction in HHF

Jardiance Safety

EMPRISE reinforce the reduction in HHF

EMPEROR Reduced Renal Outcome

EMPRISE reinforce the reduction in HHF

Jaridance Dosing